Dublin, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Prostate Cancer Pricing, Reimbursement, and Access" report to their offering.

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response measures and unattractive dosing.

This report addresses the following questions:

- How do access restrictions for prostate cancer drugs differ across markets and why?
- Which clinical trial comparators and outcomes are necessary for approval and uptake in each market?
- What impact, if any, will value assessment tools have on US reimbursement patterns?
- When and where are risk-sharing agreements useful in gaining market access?
- What are US and EU payers' and physicians' opinions on drugs targeting non-metastatic CRPC or metastatic HSPC?
- Which vaccines have a chance for uptake and reimbursement in US and EU markets?
- What does the future hold for radiotherapy Xofigo?

Key Topics Covered:

EXECUTIVE SUMMARY

MARKET CONTEXT

- Marketed prostate cancer products in the US, Japan, and five major EU markets
- Pipeline prostate cancer treatments in late-stage development
- Bibliography.

GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS

- Insights and strategic recommendations
- Payer archetypes and trends in access
- Non-metastatic castration-resistant prostate cancer
- Metastatic hormone-sensitive prostate cancer
- Evidence for the impact of earlier or combination treatment on overall resource use could gain traction with payers
- Patient-reported outcomes will become increasingly important, particularly for Xofigo
- Similar novel antiandrogens look to differentiate themselves from one another
- Providers grapple with whether or not combinations provide better long-term outcomes than sequential use of the drugs
- Advent of bundled payments will drive the need for data on optimal care pathways
- Novel immunotherapies and vaccines are welcomed alternatives, but will face similar challenges to Provenge
- Bibliography

US PRICING

- Pricing trends in the US look toward greater cost control
- Bibliography

US PAYER AND KEY OPINION LEADER INSIGHTS

- Insights and strategic recommendations
- Insurers commonly reimburse NCCN-backed indications; obtaining a category 1 recommendation will become increasingly important
- If efficacy and safety data are not differentiated from other drugs, twice-daily dosing may hinder BAY-1841788's potential
- Jevtana will be restricted to use after docetaxel, unless a substantial benefit is shown in FIRSTANA trial
- Prescribing patterns differ between medical oncologists and urologists; payers consider management of CRPC by oncologists as ideal
- Cancer Drug Coverage Parity Act of 2
- could close gap in out-of-pocket costs between oral and inpatient drugs
- New drugs mean new opportunities for contracting
- Bibliography

US REIMBURSEMENT

- Insights and strategic recommendations
- NCCN guidelines reflect FDA labels
- NCCN Evidence Blocks
- Drug value frameworks will guide the formation of clinical pathways and reimbursement criteria in the future
- Payers have limited utilization management options despite rising costs, but oncology pathways are making inroads
- Branded prostate cancer therapies are generally found on top tiers as specialty drugs
- Prior authorization and step therapy criteria from numerous payers restrict the use of Xtandi
- Bibliography

JAPAN

- Price premiums are awarded for added benefit or innovation
- Pricing of launched prostate cancer treatments
- Bibliography

PRICING IN THE FIVE MAJOR EU MARKETS FIVE MAJOR EU MARKETS PAYER AND KEY OPINION LEADER INSIGHTS

- Insights and strategic recommendations
- ESMO drug ratings praise Xofigo, but are uncertain about Xtandi's and Zytiga's role before Docetaxel
- Jevtana restricted in many European countries due to poor benefit-to-risk ratio
- Xofigo is restricted to use after docetaxel therapy in most European countries
- Real-world data are a priority for assessment bodies

FRANCE

- Insights and strategic recommendations
- ASMR rating has an impact on pricing
- The majority of new market entrants will be compared to Zytiga,
- While price is a concern, effective and tolerable vaccines will be a welcomed alternative

GERMANY

- Insights and strategic recommendations
- Positive assessment from the G-BA will impact price negotiations
- Cell therapies will find entry into the German market at the hospital level through supplemental funding mechanisms

ITALY

- Insights and strategic recommendations
- All established prostate cancer treatments are reimbursed by AIFA
- Regional health authorities perform thorough health technology assessments on new drugs
- Oral drugs subject to monitoring

SPAIN

- Insights and strategic recommendations
- National reimbursement decisions are not a major access barrier in Spain
- Regional restrictions tend to align with adverse event profiles and clinical trial exclusion Criteria
- Spanish Oncology Genitourinary Group recommendations

UK

- Insights and strategic recommendations
- NICE and SMC assessments drive reimbursement decisions
- Cancer Drugs Fund

For more information visit http://www.researchandmarkets.com/research/b3v9j9/prostate_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Prostate Cancer Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.